Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential
Pays a fixed EUR 10 million grant to take antibody-based prophylactics and therapies for epidemic-prone viruses from preclinical testing into first-in-human trials.
About
Participation of third countries where the target viruses are endemic or actively circulating is encouraged, as is participation of start-ups and SMEs to build their scientific and commercial potential. Applicants must engage with regulators early and provide a clinical-studies annex, since the topic expects clinical studies as part of the project. About 5 grants of a fixed EUR 10 million EU contr…
BiotechMedtech
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.